Article
Oncology
T. Enomoto, A. Tamiya, K. Matsumoto, Y. Adachi, K. Azuma, Y. Inagaki, S. Kouno, Y. Taniguchi, N. Saijo, K. Okishio, S. Atagi
Summary: This study evaluated the efficacy and safety of nivolumab treatment beyond progressive disease (PD) in non-small cell lung cancer (NSCLC) patients. It found no significant benefits associated with the continuation of nivolumab for advanced NSCLC patients, but suggested that continuation of nivolumab beyond PD could be a more useful option for patients without new lesions at first PD. Attention to treatment-related toxicities is important during nivolumab treatment both before and beyond PD.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Zhijie Wang, Lin Wu, Baolan Li, Ying Cheng, Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu, Dongqing Lv, Jianhua Shi, Jianjin Huang, Shaozhang Zhou, Baohui Han, Guogui Sun, Qisen Guo, Youxin Ji, Xiaoli Zhu, Sheng Hu, Wei Zhang, Qiming Wang, Yuming Jia, Ziping Wang, Yong Song, Jingxun Wu, Meiqi Shi, Xingya Li, Zhigang Han, Yunpeng Liu, Zhuang Yu, An-Wen Liu, Xiuwen Wang, Caicun Zhou, Diansheng Zhong, Liyun Miao, Zhihong Zhang, Hui Zhao, Jun Yang, Dong Wang, Yingyi Wang, Qiang Li, Xiaodong Zhang, Mei Ji, Zhenzhou Yang, Jiuwei Cui, Beili Gao, Buhai Wang, Hu Liu, Lei Nie, Mei He, Shi Jin, Wei Gu, Yongqian Shu, Tong Zhou, Jian Feng, Xinmei Yang, Cheng Huang, Bo Zhu, Yu Yao, Xiongwen Tang, Jianjun Yu, Ellen Maher, Hui Feng, Sheng Yao, Patricia Keegan, Jie Wang
Summary: The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). The study found that toripalimab plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Chongqing Tan
Summary: The study suggests that nivolumab plus ipilimumab may be more cost-effective compared to chemotherapy, especially at a WTP threshold of $100,000/QALY to $150,000/QALY. Body weight and overall survival hazard ratio are key variables influencing the cost-effectiveness ratio.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
S. Sugawara, J-S Lee, J-H Kang, H. R. Kim, N. Inui, T. Hida, K. H. Lee, T. Yoshida, H. Tanaka, C-T Yang, M. Nishio, Y. Ohe, T. Tamura, N. Yamamoto, C-J Yu, H. Akamatsu, Y. Namba, N. Sumiyoshi, K. Nakagawa
Summary: This international study evaluated nivolumab with bevacizumab and chemotherapy as a first-line treatment for nonsquamous NSCLC, showing significantly longer progression-free survival and higher objective response rates in the nivolumab group compared to the placebo group in the interim analysis. The incidence of severe treatment-related adverse events was comparable between the two groups.
ANNALS OF ONCOLOGY
(2021)
Review
Oncology
Yongfang Yao, Rameesha Fareed, Aliya Zafar, Kalsoom Saleem, Tao Huang, Yongtao Duan, Masood Ur Rehman
Summary: This article discusses the importance of genetic mutations in the treatment of non-small cell lung cancer (NSCLC), as well as new diagnostic techniques and treatment methods. It focuses on strategies for first-line and second-line therapies, as well as molecularly targeted therapy, and explores the role of treatment strategies in specific tumors. Additionally, it discusses diagnostics, new clinical trial designs, and the combination of radiotherapy and/or chemotherapy with biological therapy for cases with resistance mechanisms and palliative care.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Melodie Bonvalet, Arnaud Scherpereel, Herve Pegliasco, Corentin Richard, Francois Ghiringhelli, Arielle Elkrief, Antoine Desilets, Felix Blanc-Durand, Fabio Cumbo, Aitor Blanco, Romain Boidot, Sandy Chevrier, Romain Daillere, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Eric Deutsch, Fabrice Barlesi, David Planchard, Nicola Segata, Stephanie Martinez, Laurence Zitvogel, Jean-Charles Soria, Benjamin Besse
Summary: In addition to PD-L1 expression, biomarkers for predicting the response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. This study found that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI treatment in NSCLC patients, independent of PD-L1 expression and other factors. The relative abundance of Akk in the gut microbiome may serve as a potential biomarker for patient stratification.
Article
Medicine, General & Internal
P. Travis Courtney, Anthony T. Yip, Daniel R. Cherry, Mia A. Salans, Abhishek Kumar, James D. Murphy
Summary: The study assessed the cost-effectiveness of nivolumab-ipilimumab combination therapy as a first-line treatment for patients with advanced non-small cell lung cancer. Despite the increase in overall survival indicated by clinical trial data, the therapy was not found to be cost-effective at current prices.
Article
Pharmacology & Pharmacy
Xuezhi Hao, Aizong Shen, Bin Wu
Summary: The cost-effectiveness analysis of nivolumab plus ipilimumab for advanced non-small cell lung cancer showed that it is a cost-effective option in the United States but not in China. Sensitivity analyses confirmed the robustness of the results.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Chang Liu, Jing Gong, Hui Yu, Quan Liu, Shengping Wang, Jialei Wang
Summary: The study developed a CT-based radiomics model to predict clinical outcomes of advanced NSCLC patients treated with nivolumab. The model showed promising results in accurately predicting the risk of PFS and OS, as well as effectively stratifying patients into high and low risk subgroups.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Terenzio Cosio, Filadelfo Coniglione, Valeria Flaminio, Roberta Gaziano, Deborah Coletta, Rosalba Petruccelli, Emi Dika, Luca Bianchi, Elena Campione
Summary: Immunotherapy in oncology is replacing traditional therapies due to its specific action and limited side effects. However, bacterial infections can still occur as side effects. This case report highlights the importance of considering lifestyle and cutaneous background before starting immunotherapy for cancer treatment, with a focus on pharmacogenomics and the possibility of modified skin microbiota predisposing to cutaneous infections in patients treated with PD-1 inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Magdalena Knetki-Wroblewska, Sylwia Tabor, Aleksandra Piorek, Adam Pluzanski, Kinga Winiarczyk, Magdalena Zaborowska-Szmit, Katarzyna Zajda, Dariusz M. Kowalski, Maciej Krzakowski
Summary: This retrospective analysis confirmed the clinical benefits of nivolumab and atezolizumab in advanced NSCLC patients. Clinical and laboratory factors were identified as potential predictive factors for immunotherapy in real-life practice.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Immunology
Sijia Ren, Xinxin Xiong, Hua You, Jianfei Shen, Penghui Zhou
Summary: Combining immunotherapy with anti-angiogenesis can transform the tumor microenvironment from immunosuppressive to immune-supportive, increasing the infiltration and activation of immune cells. Therefore, this combination is a promising strategy for cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Yamin Shu, Yiling Ding, Feie Li, Qilin Zhang
Summary: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) in China. The results showed that while nivolumab plus ipilimumab improved overall survival and progression-free survival compared to chemotherapy, it was not cost-effective.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Teja Voruganti, Pamela R. Soulos, Ronac Mamtani, Carolyn J. Presley, Cary P. Gross
Summary: The introduction of immune checkpoint inhibitors has transformed the care of advanced non-small cell lung cancer, but it is unclear how outcomes have changed in clinical practice.
Article
Oncology
H. Borghaei, T. -E. Ciuleanu, J. -S Lee, A. Pluzanski, R. Bernabe Caro, M. Gutierrez, Y. Ohe, M. Nishio, J. Goldman, N. Ready, D. R. Spigel, S. S. Ramalingam, L. G. Paz-Ares, J. F. Gainor, S. Ahmed, M. Reck, M. Maio, K. J. O'Byrne, A. Memaj, F. Nathan, P. Tran, M. D. Hellmann, J. R. Brahmer
Summary: First-line nivolumab plus ipilimumab treatment in advanced NSCLC can prolong survival and have significant clinical benefits, with tumor response affecting survival.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Pavlina Chuntova, Yafei Hou, Ryosuke Naka, Akane Yamamichi, Tiffany Chen, Yitzhar Goretsky, Ryusuke Hatae, Takahide Nejo, Gary Kohanbash, Abigail L. Mende, Megan Montoya, Kira M. Downey, David Diebold, Jayne Skinner, Hong-Erh Liang, Bjoern Schwer, Hideho Okada
Summary: This study developed a new transgenic mouse model, which can be used to address clinically relevant questions and develop future immunotherapeutic strategies.
Article
Radiology, Nuclear Medicine & Medical Imaging
Hanae Takase, Osamu Togao, Kazufumi Kikuchi, Nobuhiro Hata, Ryusuke Hatae, Toru Chikui, Kenji Tokumori, Yukiko Kami, Daisuke Kuga, Yuhei Sangatsuda, Masahiro Mizoguchi, Akio Hiwatashi, Kousei Ishigami
Summary: This study found that diffusion MRI based on the gamma distribution (GD) model is useful in evaluating the IDH mutation status of glioblastomas. The GD model-derived parameters could differentiate between IDH-mutant and IDH-wildtype glioblastomas.
BRITISH JOURNAL OF RADIOLOGY
(2022)
Article
Oncology
Toshihiko Masui, Tetsuhide Ito, Izumi Komoto, Shinsuke Kojima, Yosuke Kasai, Minoru Tanabe, Kazuo Hara, Satoshi Hirano, Takuji Okusaka, Yasushi Ichikawa, Yusuke Kinugasa, Norihiro Kokudo, Atsushi Kudo, Akihiro Sakurai, Kenichi Sugihara, Hiroshi Date, Ken Haruma, Susumu Hijioka, Koichi Hirata, Hiroo Yamano, Motohiro Sakamine, Takashi Kikuchi, Masanori Fukushima, Masayuki Imamura, Shinji Uemoto
Summary: This study analyzed a registry cohort of neuroendocrine neoplasms (NEN) in Japan, providing crucial clinical data for understanding the characteristics of this disease and facilitating further research.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Masatoshi Yamazoe, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Hiroshi Yoshida, Kentaro Hashimoto, Kazutaka Hosoya, Tatsuya Ogimoto, Hitomi Ajimizu, Hironori Yoshida, Ryo Itotani, Yuichi Sakamori, Kiyomitsu Kuninaga, Wataru Aoki, Toyohiro Hirai
Summary: TKIs have shown therapeutic effects in treating ROS1-rearranged NSCLC, but the survival of tumor cells during initial treatment is a challenge. This study identified YAP1 as a factor involved in cell survival during lorlatinib treatment and found that inhibition of YAP1 enhanced the sensitivity of tumor cells to lorlatinib. YAP1 exerted its prosurvival effect through the reactivation of AKT. Combination therapy targeting both YAP1 and ROS1 achieved sustained tumor remission in vivo.
Article
Urology & Nephrology
Mikio Sugimoto, Takuma Kato, Yoichiro Tohi, Yosuke Shimizu, Ryuji Matsumoto, Takahiro Inoue, Yutaka Takezawa, Kimihiko Masui, Hiroshi Sasaki, Hiromi Hirama, Shiro Saito, Shin Egawa, Toshiyuki Kamoto, Satoshi Teramukai, Shinsuke Kojima, Takashi Kikuchi, Yoshiyuki Kakehi
Summary: This study aimed to investigate the efficacy and safety of enzalutamide after combined androgen blockade for recurrence. The results showed that enzalutamide effectively managed non-metastatic castration-resistant prostate cancer and had high survival rates.
Article
Cell Biology
Shingo Matsushima, Masahiko Ajiro, Kei Iida, Kenji Chamoto, Tasuku Honjo, Masatoshi Hagiwara
Summary: The synthetic compound RECTAS can induce the production of splice-neoantigens, boosting antitumor immune responses and enhancing immune checkpoint blockade efficacy.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Health Policy & Services
Shinsuke Kojima, Takashi Kikuchi, Yasumasa Kakei, Hisatomo Kowa, Yasuji Yamamoto, Hiroyuki Kajita, Tohmi Osaki, Masanori Fukushima, Ryoma Kayano, Yoji Nagai
Summary: This study explored the use of cognitive function-related simple questions to identify older individuals at risk of needing long-term care. The results showed that non-responders had a higher cumulative incidence of long-term care compared to responders. Among the responders, the incidence of long-term care increased with the number of negative answers to cognitive function-related questions. All three cognitive function-related questions were predictive of the need for long-term care, with the question about memory loss having the highest hazard ratio for predicting the need for long-term care accompanied by dementia.
HEALTH RESEARCH POLICY AND SYSTEMS
(2022)
Article
Medicine, General & Internal
Shuji Matsumoto, Megumi Shimodozono, Tomokazu Noma, Kodai Miyara, Tetsuya Onoda, Rina Ijichi, Takashi Shigematsu, Akira Satone, Hidenobu Okuma, Makiko Seto, Masanori Taketsuna, Hideaki Kaneda, Miyuki Matsuo, Shinsuke Kojima
Summary: This study evaluated the effectiveness of the Walkaide(R) device for improving walking ability and lower extremity function in Japanese post-stroke patients with foot drop. The patients were randomly assigned to either the functional electrical stimulation (FES) group or the control group. After 8 weeks of training, using the Walkaide device did not significantly improve the 6-minute walk distance in the FES group compared to the control group. The trial was registered at UMIN000020604.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Itsuki Yuasa, Masatsugu Hamaji, Hiroaki Ozasa, Yuichi Sakamori, Hironori Yoshida, Yojiro Yutaka, Toshi Menju, Toyohiro Hirai, Hiroshi Date
Summary: This study aimed to investigate the short- and long-term outcomes of patients who received immune checkpoint inhibitors (ICIs) for postoperative recurrence of non-small cell lung cancer (NSCLC). The results showed that the median progression-free survival (PFS) and overall survival (OS) of patients receiving ICIs were 3.2 and 17.5 months, respectively. For patients receiving ICIs as first-line therapy, the median PFS and OS were 6.3 and 25.0 months, respectively. Smoking history and non-squamous cell histology were associated with more favorable PFS in these patients.
GENERAL THORACIC AND CARDIOVASCULAR SURGERY
(2023)
Article
Oncology
Tatsuya Ogimoto, Hiroaki Ozasa, Hironori Yoshida, Takashi Nomizo, Tomoko Funazo, Hiroshi Yoshida, Kentaro Hashimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Hitomi Ajimizu, Takahiro Tsuji, Yuichi Sakamori, Kiyomitsu Kuninaga, Satoshi Morita, Toyohiro Hirai
Summary: This study investigated the association between CD47 gene polymorphisms and the therapeutic effect of nivolumab in patients with NSCLC. The results showed that the G/G genotype of CD47 polymorphisms was significantly associated with longer progression-free survival and overall survival. Therefore, CD47 gene polymorphisms may serve as a novel predictive biomarker for nivolumab efficacy in advanced NSCLC patients.